0013.HK in “China Becomes Pharma's Global R&D Engine”
HUTCHMED (China) Limited
HUTCHMED validated the China-to-global model by developing fruquintinib in China and licensing ex-China rights to Takeda, which has launched the oncology drug internationally.
0013.HK impact map — “China Becomes Pharma's Global R&D Engine”
How this story travels from the headline to 0013.HK’s own business — positive, negative or mixed, direct or indirect, the mechanism, and how strong the exposure is.
Loading 0013.HK impact map…
Price history, marked with story events
Aug 27, 2025 – Aug 28, 2026 · 247 sessions
Prices updated during market hours · refreshed about every 30 minutes while the market is open · delayed data, not for trading decisions
Numbered markers tie price moves to earnings, trial or study results, management comments and analyst or demand data. Loading events…
Full story
China Becomes Pharma's Global R&D Engine
Western drugmakers are licensing clinically validated Chinese molecules rather than relying solely on expensive in-house discovery.
BULL side — HUTCHMED validated the China-to-global model by developing fruquintinib in China and licensing ex-China rights to Takeda, which has launched the oncology drug internationally.
Read the full China Becomes Pharma's Global R&D Engine story